Q-omics provides the consensus-scored NLGN4X profile across patient tissues and cancer cell-line models. NLGN4X expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NLGN4X is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, NLGN4X RNA expression shows 15,897 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, COAD, and TGCT as cancer lineages where NLGN4X shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLGN4X — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLGN4X survival associations across molecular data types. NLGN4X RNA expression shows survival associations in the most cancer types (24), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLGN4X RNA expression–survival associations across cancer types. High NLGN4X expression shows unfavorable associations in UVM, LUAD and HNSC, but favorable associations in KIRC, SKCM and CHOL. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NLGN4X RNA expression.
This table summarizes NLGN4X tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NLGN4X. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLGN4X shows lower tumor expression in COAD, BRCA, CHOL and READ and higher tumor expression in HNSC and KICH. The COAD box plot shows higher NLGN4X RNA expression in normal versus tumor tissue (log2 FC = −1.091, t-test p < 0.001).
This table shows molecular features associated with NLGN4X in patient tissues and cancer cell lines. In patient samples, NLGN4X shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NLGN4X RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
